TrialBlood advances2024

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

Meletios A Dimopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.